Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Opthea Limited to participate in investor meetings at Leerink Partners Global Biopharma Conference in Miami, Florida. Opthea is a clinical-stage biopharmaceutical company focusing on retinal disease therapies.
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
About Opthea
Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.
Authorized for release to ASX by Fred Guerard, CEO
Investor Enquiries
PJ Kelleher
LifeSci Advisors
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media
Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399
Email: info@opthea.com
Opthea Limited’s ticker symbol is OPT.
Opthea Limited is a clinical-stage biopharmaceutical company developing therapies for retinal diseases.
Opthea Limited will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference in Miami, Florida.
The Leerink Partners Global Biopharma Conference will be held on March 11-13, 2024.
NASDAQ:OPT
OPT Rankings
#5052 Ranked by Stock Gains
OPT Latest News
OPT Stock Data
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Health Technology, Pharmaceuticals: Other, Biotechnology
Australia
Melbourne
About OPT
opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea’s lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com
